Guggenheim Initiates Coverage on Rapport Therapeutics with Buy Rating
Guggenheim has initiated coverage on Rapport Therapeutics with a Buy rating and a price target of $65.00 per share.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.